PMC:6909918 / 13775-14294 JSONTXT

{"project":"2_test","denotations":[{"id":"31790382-25981818-69134711","span":{"begin":44,"end":46},"obj":"25981818"},{"id":"31790382-23177514-69134712","span":{"begin":58,"end":59},"obj":"23177514"},{"id":"31790382-29946728-69134713","span":{"begin":70,"end":71},"obj":"29946728"},{"id":"31790382-25970050-69134714","span":{"begin":84,"end":85},"obj":"25970050"},{"id":"31790382-29215955-69134715","span":{"begin":99,"end":100},"obj":"29215955"}],"text":"The five published RCTs identified, CONCUR [11], CORRECT [4], FRESCO [7], RECOURSE [5], and TERRA [6], which included 2,604 patients, were used in network meta-analysis. All the patients included in these five published RCTs were patients who were refractory to previous drug treatment who had progressed on standard chemotherapy, including oxaliplatin, irinotecan, and 5-fluoropyrimidine (5-FU), and were refractory to targeted agents, including bevacizumab and anti-EGFR treatment in patients with RAS wild-type mCRC."}